The essential Q3 (November-January) feedback is that the FDA process progresses without significant internal or external disruptions. Biovica is on track for submitting supplementary results in May, and the company is also on track to secure a likely conclusive subsequent FDA decision in July to August, in our view.

https://www.redeye.se/research/836333/biovica-q4-the-fda-process-is-live-and-biovica-prepares-for-the-launch-with-expanding-clinical-support?utm_source=finwire&utm_medium=RSS

Redeye